Regulation of nuclear factor-kB nuclear translocation by agmatine in primary cultured astrocytes following ischemic insults
Year: 2005
Type: dissertation
Abstract: Agmatine is a primary amine formed by the decarboxylation of L-arginine and is an endogenous clonidine-displacing substance synthesized in mammalian brain.Many studies suggest that agmatine reduces various brain injury.We investigated the protective effect of agmatine in the primary cultured astrocytes under ischemic-like injury.Agmatine protected the astrocytes from necrotic and apoptotic cell death under oxygen-glucose deprivation.Especially, agmatine decreased necrotic cells in OGD phase, but at the end of OGD-R, agmatine reduced delayed apoptotic cells.These protections were associated with an induction of nuclear factor-κB (NF-κB) nuclear translocation.Western blotting analysis showed that agmatine increased nuclear translocation of NF-κB, which were inhibited by the inhibitor (MG132).Futhermore, agmatine increased the expression of p-IkBα and p-IKKα/β in astrocytes under ischemic conditions.Agmatine also regulated phosphorylation of p42/p44 MAPK (ERK1/2) and c-Jun N-terminal kinase (JNK), which were attenuated by U0126 or SP600125, respectively.Especially, the expression of p-ERK was slightly increased with agmatine, while that of p-JNK was significantly reduced in astrocytes under ischemic injury.However, phosphorylated p38 was not influenced by agmatine.But these MAPKs regulated by agmatine regulated cell death in OGD treated astrocytes.NF-κB nuclear translocation by agmatine was linked with the expression of other anti-apoptotic protein such as Bcl-2, and the Bcl-2 expression was downregulated by MG132 in astrocytes under OGD.These results demonstrated that neuroprotective effect of agmatine seemed to be related with the regulation of Bcl-2 via NF-κB pathway and the regulation of MAPKs expression by agmatine did not seemed to be related with NF-κ B translocation directly.
Author: 윤성환
Language: English
Topic: NF-κB Signaling Pathways
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W2939935552
